Search Results

NeuroPointDX, a division of Stemina Biomarker Discovery, today announced the appointment of two new board members with extensive experience in the development and commercialization of new molecular diagnostic tests. Barbara Handelin, PhD was founding Director of the DNA Diagnostics Lab at Integrated Genetics (acquired by LabCorp @ $925M), and Tony Shuber was Chief Technology Officer and cofounder of Exact Science Corporati

NeuroPointDx, a division of Stemina Biomarker Discovery, today announced the commercial launch of its NPDX AA test, which identifies metabolic subtypes associated with autism spectrum disorder (ASD).

NeuroPointDX today announced the appointment of Marvin Natowicz, M.D., Ph.D., medical geneticist and clinical pathologist at the Cleveland Clinic and Professor of Pathology at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.

Clinician and leader in development of personalized medicine approaches to autism spectrum disorder and other neurodevelopmental conditions

Findings from continued analyses of data from 1,100-patient clinical study identify additional metabolic subtypes that may indicate increased risk of ASD diagnosis

Company Will Present New Data from the 1,100 Patient Clinical Study, the Children’s Autism Metabolome Project

New Findings from the CAMP Study, a 1,102 Subject Study of the Metabolism of Children with ASD, Published in Autism Research

Continued analysis of samples from the Children’s Autism Metabolome Project (CAMP), the most comprehensive clinical study of metabolism in children who have autism spectrum disorder (ASD) conducted to date, has identified three new areas of metabolism that affect the biology of children with ASD

Metabolic signatures in the blood of children with autism spectrum disorder (ASD) may lead to earlier diagnosis of the condition for some children, according to newly published research